focus -WSS

focus

author：fashion 2025-09-06 04:15:27 - browse：2313

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： A preacher's new calling: Diversifying neuroscience research

WSS

Ohioans vote in high

Stories you might have missed in 2023: health, science, medicine

Hospitals use virtual reality to design more inclusive rooms for kids

FDA early review: GLP

At JPM 2024, hospital systems pitch financial strength to investors

JPM pitch from hospitals? Revenue streams outside of patient care

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Judge rejects Trump's counterclaim against E. Jean Carroll

Virginia high school admissions case could be legal follow

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Activists slam private health insurers over coverage restrictions

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Continuity nursing helped my family in our darkest PICU moments

Merck to acquire Harpoon Therapeutics for $680 million

Wildfire smoke exposes gaps in outdoor worker protections

JPM pitch from hospitals? Revenue streams outside of patient care

Wikipedia

Boston Scientific acquires urology company Axonics for $3.7 billion

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Germany receives 178 compensation applications from gay servicepeople over discrimination

Life science postdocs should get big pay hike, NIH panel says

Study suggests new cause of Down syndrome: cells linked to aging

At JPM 2024, hospital systems pitch financial strength to investors

hotspot

explore

explore

focus